BioCentury | Jan 22, 2021
Management Tracks

Woodman to guide Eisai’s cancer unit; plus Mengyu Lu joins Kirkland & Ellis in Hong Kong, and Splice Bio, Tarsus, Verastem, Fulcrum and more

...is president and CEO of Vivet Therapeutics, and was COO of GenSight Biologics S.A.Ophthalmic company Tarsus Pharmaceuticals Inc....
BioCentury | Oct 17, 2020
Finance

Praxis sees strongest first-day among trio of IPOs as NASDAQ nears $16B raised in fresh paper

...developing oligonucleotides and small molecules for HBV, liver diseases including non-alcoholic steatohepatitis (NASH) and SARS-CoV-2 infection. Tarsus Pharmaceuticals Inc....
...endothelial growth factor CVEGF-D - Vascular endothelial growth factor D Paul Bonanos Aligos Therapeutics Inc. Praxis Precision Medicines Inc. Tarsus Pharmaceuticals Inc....
BioCentury | Aug 15, 2020
Management Tracks

Myriad chooses Diaz as new CEO; plus changes at Novocure, Werewolf, Jasper, Avacta, Tarsus and more

...unit. He was SVP, head of global clinical operations at Autolus Therapeutics plc (NASDAQ:AUTL).Ophthalmology company Tarsus Pharmaceuticals Inc....
...was senior medical director at Johnson & Johnson (NYSE:JNJ). Robin Sawka Novocure Ltd. Werewolf Therapeutics Jasper Therapeutics Inc. Avacta Group plc Tarsus Pharmaceuticals Inc. Bicycle...
BioCentury | Jul 18, 2020
Management Tracks

Genzyme vet Modur joins Zikani; plus Scholar Rock, Poseida, Ribon, Kiadis and more

...at Insulet Corp. ViaCyte is developing cell replacement therapies for patients with diabetes. Ophthalmology company Tarsus Pharmaceuticals Inc....
...LogicBio Therapeutics Inc. (NASDAQ:LOGC). Robin Sawka, BioCentury Staff ViaCyte Inc. Ribon Therapeutics Inc. Innate Pharma S.A. Kiadis Pharma N.V. Zikani Therapeutics Inc. Tarsus Pharmaceuticals Inc. MaaT...
BioCentury | Jan 16, 2020
Finance

Frazier taking new company creation angle with $617M fund

...to many possibilities and is generally agnostic to therapeutic areas. He pointed to ophthalmic play Tarsus Pharmaceuticals Inc....
BioCentury | Jan 8, 2020
Company News

Tarsus targets mites driving inflammatory eye disease with $60M series B

...included Frazier Healthcare Partners, Flying L Partners, Visionary Ventures, Aperture Venture Partners and Horowitz Group. Tarsus Pharmaceuticals Inc....
...undisclosed series A round from one of the company's series B investors. Karen Tkach Tuzman, Associate Editor Tarsus Pharmaceuticals Inc. blepharitis Demodex...
Items per page:
1 - 6 of 6
BioCentury | Jan 22, 2021
Management Tracks

Woodman to guide Eisai’s cancer unit; plus Mengyu Lu joins Kirkland & Ellis in Hong Kong, and Splice Bio, Tarsus, Verastem, Fulcrum and more

...is president and CEO of Vivet Therapeutics, and was COO of GenSight Biologics S.A.Ophthalmic company Tarsus Pharmaceuticals Inc....
BioCentury | Oct 17, 2020
Finance

Praxis sees strongest first-day among trio of IPOs as NASDAQ nears $16B raised in fresh paper

...developing oligonucleotides and small molecules for HBV, liver diseases including non-alcoholic steatohepatitis (NASH) and SARS-CoV-2 infection. Tarsus Pharmaceuticals Inc....
...endothelial growth factor CVEGF-D - Vascular endothelial growth factor D Paul Bonanos Aligos Therapeutics Inc. Praxis Precision Medicines Inc. Tarsus Pharmaceuticals Inc....
BioCentury | Aug 15, 2020
Management Tracks

Myriad chooses Diaz as new CEO; plus changes at Novocure, Werewolf, Jasper, Avacta, Tarsus and more

...unit. He was SVP, head of global clinical operations at Autolus Therapeutics plc (NASDAQ:AUTL).Ophthalmology company Tarsus Pharmaceuticals Inc....
...was senior medical director at Johnson & Johnson (NYSE:JNJ). Robin Sawka Novocure Ltd. Werewolf Therapeutics Jasper Therapeutics Inc. Avacta Group plc Tarsus Pharmaceuticals Inc. Bicycle...
BioCentury | Jul 18, 2020
Management Tracks

Genzyme vet Modur joins Zikani; plus Scholar Rock, Poseida, Ribon, Kiadis and more

...at Insulet Corp. ViaCyte is developing cell replacement therapies for patients with diabetes. Ophthalmology company Tarsus Pharmaceuticals Inc....
...LogicBio Therapeutics Inc. (NASDAQ:LOGC). Robin Sawka, BioCentury Staff ViaCyte Inc. Ribon Therapeutics Inc. Innate Pharma S.A. Kiadis Pharma N.V. Zikani Therapeutics Inc. Tarsus Pharmaceuticals Inc. MaaT...
BioCentury | Jan 16, 2020
Finance

Frazier taking new company creation angle with $617M fund

...to many possibilities and is generally agnostic to therapeutic areas. He pointed to ophthalmic play Tarsus Pharmaceuticals Inc....
BioCentury | Jan 8, 2020
Company News

Tarsus targets mites driving inflammatory eye disease with $60M series B

...included Frazier Healthcare Partners, Flying L Partners, Visionary Ventures, Aperture Venture Partners and Horowitz Group. Tarsus Pharmaceuticals Inc....
...undisclosed series A round from one of the company's series B investors. Karen Tkach Tuzman, Associate Editor Tarsus Pharmaceuticals Inc. blepharitis Demodex...
Items per page:
1 - 6 of 6